Syntimmune—Stock-for-cash transaction

Completed the sale of this biotechnology company to Alexion in a stock-for-cash transaction. We represented Syntimmune founders Richard Blumberg, MD, and Laurence Blumberg, MD, as well as their family office and the AFB Fund, the initial institutional investor and largest common stockholder. Syntimmune develops novel therapies for a wide range of autoimmune disorders, driven by the founders’ discoveries related to the unique role of FcRn in mediating immune response.